{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:50Z","timestamp":1791559430384,"version":"4.3.4"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have been increasingly integrated into first-line systemic treatment strategies for advanced or metastatic gastroesophageal cancers. ICI-associated myocarditis is an uncommon but potentially fatal immune-related adverse event. Early recognition is particularly challenging when severe myocardial injury precedes typical cardiac symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 71-year-old man with advanced gastric adenocarcinoma with liver, abdominal cavity, and retroperitoneal metastases received first-line oxaliplatin, S-1, and sintilimab on December 30, 2025. Baseline cardiac biomarkers before treatment were within normal limits, and baseline echocardiography showed preserved left ventricular systolic function without regional wall motion abnormality. He was rehospitalized for his second course of chemotherapy on January 23, 2026, without chest pain, palpitations, or dyspnea. Routine laboratory testing unexpectedly revealed extreme myocardial injury, with NT-proBNP 1263 pg\/ml, cardiac troponin I (cTnI) &amp;gt;25, 000 ng\/L, creatine kinase (CK) 5, 205 U\/L, myoglobin (MYO) &amp;gt;1, 000 \u03bcg\/L, and CK-MB mass 112.39 \u03bcg\/L. Electrocardiography remained broadly similar to the baseline tracing of sinus rhythm with complete right bundle branch block, without a diagnostic acute ST-segment elevation pattern. Coronary angiography did not identify an acute culprit lesion sufficient to explain the biomarker elevation. Serial echocardiography showed new wall motion abnormality and progressive decline in left ventricular ejection fraction. Given the temporal relationship with PD-1 blockade, the absence of an angiographic culprit lesion, evolving myocardial dysfunction, and marked cardiac biomarker elevation, a clinical diagnosis of probable sintilimab-associated myocarditis was made. Intravenous methylprednisolone, intravenous immunoglobulin, and intensive supportive treatment were administered. However, myocardial biomarkers remained markedly abnormal, and overt cardiac symptoms emerged only later in the course, followed by hemodynamic instability and terminal circulatory collapse. The patient died of fulminant myocarditis with cardiogenic shock on February 1, 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates a biomarker-first presentation of probable ICI-associated myocarditis, in which catastrophic myocardial injury was detected before typical cardiac symptoms became apparent. Absence of chest pain or dyspnea should not reassure clinicians when marked troponin elevation occurs shortly after ICI exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1889059","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:35:59Z","timestamp":1787114159000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Asymptomatic extreme troponin elevation preceding fatal clinically suspected sintilimab-associated myocarditis: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Siqing","family":"Zhao","sequence":"first","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Song","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Lu","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chang","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC Cardiooncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/00033197231201929","article-title":"Immune-checkpoint inhibitor-related myocarditis: Where we are and where we will go","volume":"75","author":"Vergara","year":"2024","journal-title":"Angiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1832047","article-title":"Case report: Two cases of PD-1 inhibitor-associated myocarditis with bidirectional ventricular tachycardia","volume":"17","author":"Lian","year":"2026","journal-title":"Front Immunol"},{"key":"B8","volume-title":"Chinese Society of Clinical Oncology (Csco) Clinical Practice Guidelines in Cardio-Oncology 2025","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42071","article-title":"A systematic review of myocarditis induced by immune checkpoint inhibitors: How concerning is the most common cardiotoxicity of immune checkpoint inhibitors","volume":"15","author":"Moradi","year":"2023","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004699","article-title":"Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept","volume":"10","author":"Nguyen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1817","article-title":"Mechanisms maintaining peripheral tolerance","volume":"11","author":"Mueller","year":"2010","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0447-OA","article-title":"Histopathologic characterization of myocarditis associated with immune checkpoint inhibitor therapy","volume":"144","author":"Sobol","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-7820886\/v1","article-title":"Troponin or not troponin: What is the impact of regular cardiac monitoring for patients treated with immunotherapy","author":"Cailleteau","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.12.003","article-title":"Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience","volume":"204","author":"Fernandes","year":"2026","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1889059\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:36:12Z","timestamp":1787114172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1889059\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1889059"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1889059","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1889059"}}